Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).
Inclusion Criteria:
Exclusion Criteria:
Note: Other protocol-defined inclusion/exclusion criteria apply
Ciudad Autónoma de Buenos Aires, Buenos Aires 1280, Argentina
Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
ABB, Buenos Aires F.D. C1199ABB, Argentina
Bunkyo Ku, Tokyo 113-8677, Japan
Seoul, Seoul-teukbyeolsi [Seoul] 03722, South Korea
Istanbul, 34440, Turkey (Türkiye)